Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Identification of a Plasmodium falciparum inhibitor-2 motif involved in the binding and regulation activity of protein phosphatase type 1.

Fréville A, Tellier G, Vandomme A, Pierrot C, Vicogne J, Cantrelle FX, Martoriati A, Cailliau-Maggio K, Khalife J, Landrieu I.

FEBS J. 2014 Oct;281(19):4519-34. doi: 10.1111/febs.12960. Epub 2014 Sep 8.

2.

Plasmodium falciparum encodes a conserved active inhibitor-2 for Protein Phosphatase type 1: perspectives for novel anti-plasmodial therapy.

Fréville A, Cailliau-Maggio K, Pierrot C, Tellier G, Kalamou H, Lafitte S, Martoriati A, Pierce RJ, Bodart JF, Khalife J.

BMC Biol. 2013 Jul 9;11:80. doi: 10.1186/1741-7007-11-80.

3.

Plasmodium falciparum inhibitor-3 homolog increases protein phosphatase type 1 activity and is essential for parasitic survival.

Fréville A, Landrieu I, García-Gimeno MA, Vicogne J, Montbarbon M, Bertin B, Verger A, Kalamou H, Sanz P, Werkmeister E, Pierrot C, Khalife J.

J Biol Chem. 2012 Jan 6;287(2):1306-21. doi: 10.1074/jbc.M111.276865. Epub 2011 Nov 28.

4.

Small molecules targeted to a non-catalytic "RVxF" binding site of protein phosphatase-1 inhibit HIV-1.

Ammosova T, Platonov M, Yedavalli VR, Obukhov Y, Gordeuk VR, Jeang KT, Kovalskyy D, Nekhai S.

PLoS One. 2012;7(6):e39481. doi: 10.1371/journal.pone.0039481. Epub 2012 Jun 29.

6.

Importance of a surface hydrophobic pocket on protein phosphatase-1 catalytic subunit in recognizing cellular regulators.

Gibbons JA, Weiser DC, Shenolikar S.

J Biol Chem. 2005 Apr 22;280(16):15903-11. Epub 2005 Feb 9.

7.

Why is the Plasmodium falciparum hexose transporter a promising new drug target?

Joët T, Morin C, Fischbarg J, Louw AI, Eckstein-Ludwig U, Woodrow C, Krishna S.

Expert Opin Ther Targets. 2003 Oct;7(5):593-602. Review.

PMID:
14498822
8.

Identification of AKAP79 as a protein phosphatase 1 catalytic binding protein.

Le AV, Tavalin SJ, Dodge-Kafka KL.

Biochemistry. 2011 Jun 14;50(23):5279-91. doi: 10.1021/bi200089z. Epub 2011 May 16.

9.

Characterization of a unique aspartate-rich protein of the SET/TAF-family in the human malaria parasite, Plasmodium falciparum, which inhibits protein phosphatase 2A.

Dobson S, Kumar R, Bracchi-Ricard V, Freeman S, Al-Murrani SW, Johnson C, Damuni Z, Chakrabarti D, Barik S.

Mol Biochem Parasitol. 2003 Feb;126(2):239-50.

PMID:
12615323
10.

Plasmodium falciparum protein phosphatase type 1 functionally complements a glc7 mutant in Saccharomyces cerevisiae.

Bhattacharyya MK, Hong Z, Kongkasuriyachai D, Kumar N.

Int J Parasitol. 2002 Jun;32(6):739-47.

PMID:
12062492
11.

Identification of Plasmodium falciparum Translation Initiation eIF2β Subunit: Direct Interaction with Protein Phosphatase Type 1.

Tellier G, Lenne A, Cailliau-Maggio K, Cabezas-Cruz A, Valdés JJ, Martoriati A, Aliouat el M, Gosset P, Delaire B, Fréville A, Pierrot C, Khalife J.

Front Microbiol. 2016 May 26;7:777. doi: 10.3389/fmicb.2016.00777. eCollection 2016.

12.

Structures of P. falciparum protein kinase 7 identify an activation motif and leads for inhibitor design.

Merckx A, Echalier A, Langford K, Sicard A, Langsley G, Joore J, Doerig C, Noble M, Endicott J.

Structure. 2008 Feb;16(2):228-38. doi: 10.1016/j.str.2007.11.014.

13.

PhosphoTyrosyl phosphatase activator of Plasmodium falciparum: identification of its residues involved in binding to and activation of PP2A.

Vandomme A, Fréville A, Cailliau K, Kalamou H, Bodart JF, Khalife J, Pierrot C.

Int J Mol Sci. 2014 Feb 11;15(2):2431-53. doi: 10.3390/ijms15022431.

14.

Analysis of the interactome of the Ser/Thr Protein Phosphatase type 1 in Plasmodium falciparum.

Hollin T, De Witte C, Lenne A, Pierrot C, Khalife J.

BMC Genomics. 2016 Mar 17;17:246. doi: 10.1186/s12864-016-2571-z.

16.

Peptide inhibitors of the malaria surface protein, apical membrane antigen 1: identification of key binding residues.

Lee EF, Yao S, Sabo JK, Fairlie WD, Stevenson RA, Harris KS, Anders RF, Foley M, Norton RS.

Biopolymers. 2011 May;95(5):354-64. doi: 10.1002/bip.21582. Epub 2011 Jan 6.

17.
18.

In vitro resistance selections for Plasmodium falciparum dihydroorotate dehydrogenase inhibitors give mutants with multiple point mutations in the drug-binding site and altered growth.

Ross LS, Gamo FJ, Lafuente-Monasterio MJ, Singh OM, Rowland P, Wiegand RC, Wirth DF.

J Biol Chem. 2014 Jun 27;289(26):17980-95. doi: 10.1074/jbc.M114.558353. Epub 2014 Apr 29.

19.

Regulation of protein phosphatase type 1 and cell cycle progression by PfLRR1, a novel leucine-rich repeat protein of the human malaria parasite Plasmodium falciparum.

Daher W, Browaeys E, Pierrot C, Jouin H, Dive D, Meurice E, Dissous C, Capron M, Tomavo S, Doerig C, Cailliau K, Khalife J.

Mol Microbiol. 2006 May;60(3):578-90.

20.

Structural characterization and inhibition of the Plasmodium Atg8-Atg3 interaction.

Hain AU, Weltzer RR, Hammond H, Jayabalasingham B, Dinglasan RR, Graham DR, Colquhoun DR, Coppens I, Bosch J.

J Struct Biol. 2012 Dec;180(3):551-62. doi: 10.1016/j.jsb.2012.09.001. Epub 2012 Sep 13.

Items per page

Supplemental Content

Write to the Help Desk